Genspera Inc  

(Public, OTCMKTS:GNSZ)   Watch this stock  
Find more results for Genspera, Inc.�
0.800
-0.030 (-3.61%)
Mar 31 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.80 - 0.83
52 week 0.54 - 1.33
Open 0.81
Vol / Avg. 2,000.00/18,856.00
Mkt cap 26.84M
P/E     -
Div/yield     -
EPS -0.26
Shares 33.55M
Beta 0.22
Inst. own 0%
Mar 24, 2015
Genspera Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Feb 9, 2015
Genspera Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 19, 2015
Genspera Inc at Noble Financial Equity Conference
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -160.76% -164.20%
Return on average equity -346.42% -1993.23%
Employees 2 -
CDP Score - -

Address

2511 N. Loop 1604 W. Suite 204
San Antonio, TX 78258
United States - Map
+1-210-4798112 (Phone)
+1-800-2535177 (Fax)

Website links

Description

GenSpera Inc. (GenSpera) is a development-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors including prostate, liver, brain and other cancers. A prodrug is an inactive precursor of a drug that is converted into its active form only at the site of the tumor. The Company has four prodrug candidates: G-202, G-114, G-115 and G-301. The Company�s focus is the clinical development of its compound, G-202, a therapeutic agent with a mechanism of action. G-202 is in Phase II Clinical Trial. G-114 is validated efficacy in pre-clinical animal models. Pilot toxicology is completed for G-115. G-301 is validated efficacy in pre-clinical animal models. The Company is also conducting a Phase II clinical trial to test the utility of G-202 in patients with hepatocellular carcinoma (liver cancer).

Officers and directors

Craig A. Dionne Ph.D. Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer
Age: 57
Russell Richerson Ph.D. Chief Operating Officer, Secretary
Age: 63
Peter E. Grebow Ph.D. Independent Director
Age: 68
Bo Jesper Hansen M.D., Ph.D. Independent Director
Age: 57
Scott V. Ogilvie Independent Director
Age: 60